Chicago Capital LLC Boosts Holdings in Evolent Health, Inc. (NYSE:EVH)

Chicago Capital LLC grew its holdings in shares of Evolent Health, Inc. (NYSE:EVH) by 209.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,134 shares of the technology company’s stock after buying an additional 21,061 shares during the quarter. Chicago Capital LLC’s holdings in Evolent Health were worth $350,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in EVH. R Squared Ltd bought a new stake in shares of Evolent Health during the 4th quarter valued at about $31,000. Quarry LP bought a new position in Evolent Health in the 2nd quarter valued at about $32,000. Covestor Ltd raised its holdings in Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares during the period. Finally, KBC Group NV boosted its position in shares of Evolent Health by 124.6% during the 4th quarter. KBC Group NV now owns 6,741 shares of the technology company’s stock valued at $76,000 after purchasing an additional 3,739 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Canaccord Genuity Group cut their target price on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Needham & Company LLC started coverage on Evolent Health in a research report on Friday, January 10th. They set a “buy” rating and a $15.00 price objective for the company. Citigroup decreased their target price on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, January 10th. JMP Securities cut their price objective on Evolent Health from $27.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Friday, January 10th. Finally, Stephens cut their target price on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $18.38.

Evolent Health Stock Down 2.3 %

NYSE EVH opened at $10.21 on Tuesday. The stock’s 50 day simple moving average is $11.28 and its 200 day simple moving average is $19.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a one year low of $9.74 and a one year high of $35.00. The firm has a market cap of $1.19 billion, a PE ratio of -11.21 and a beta of 1.45.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $621.40 million during the quarter, compared to the consensus estimate of $625.58 million. During the same period in the prior year, the firm earned $0.19 earnings per share. As a group, sell-side analysts forecast that Evolent Health, Inc. will post 0.24 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.